Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation

Abstract Primary mediastinal large B-cell lymphoma (PMBL) is a subtype of non-Hodgkin B-cell lymphoma that most frequently occurs in young adults and is thought to reflect neoplastic transformation of thymic medullary B-cells. We characterized 59 PMBL cases from the Atlas of Blood Cancer Genomes Project. The cohort was predominantly young (median age 35), female (62%), and included individuals from diverse racial backgrounds. Most individuals presented with low-stage disease, favorable ECOG performance status, and high overall survival rate at last follow-up (89%). Whole transcriptome sequencing of 49 PMBL cases revealed gene expression profiles distinct from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), both activated B cell-like (ABC) and germinal center B cell-like (GCB) cell-of-origin subtypes. PMBLs showed significantly higher expression of thymic B cell-associated genes (p=0.032), supporting their presumed thymic origin. Whole exome and targeted sequencing confirmed recurrent mutations in JAK/STAT, NF-κB signaling, and DNA damage response pathways, with frequent aberrant somatic hypermutation (aSHM) affecting multiple genes. Recurrent copy number alterations included gains at 9p and 12, and losses at 13q. As in prior studies, CIITA rearrangements with diverse partners were recurrent. Although PMBL generally demonstrates excellent outcomes, aSHM-positive cases exhibited inferior progression-free survival (p=0.031), suggesting aSHM as a potential adverse prognostic marker. Our findings further refine the genomic landscape of PMBL and provide new insights into the biology of this neoplasm, with implications for prognostic stratification.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2026-11-11
DOI
https://doi.org/10.1158/2767-9764.crc-26-0077
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation

Dennis Owusu, Jiong Yan, Ayush Batra, Govind Bhagat et al.
Cancer Research Communications
Lymphoma Diagnosis and Treatment
article

Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation

Dennis Owusu, Jiong Yan, Ayush Batra, Govind Bhagat, Devang Thakkar, Matthew Stuart McKinney, Chad M. McCall, Eric D. Hsi, Clay Parker, Lanie E. Happ, Abner Louissaint, Elizabeth Thacker, Ridas Juskevicius, Kikkeri N. Naresh, Mateo Mejía Saldarriaga, Rebecca J. Leeman‐Neill, Sarah Lynn Ondrejka, Shin Yeu Ong, Jennifer R. Shingleton, Amy Chadburn, David L. Jaye, Amir Behdad, Dennis P. O’Malley, Cassandra Love, Rashmi S. Goswami, Carlos Galvez, Chee Leong Cheng, Jean Louise Koff, Tushar Dave, Sandeep S. Davé, Dina Sameh Soliman, Mary Ann Arildsen, Shaoying Li, Andrew Evans, Leonardo P. A. Biral
article en

Abstract

Abstract Primary mediastinal large B-cell lymphoma (PMBL) is a subtype of non-Hodgkin B-cell lymphoma that most frequently occurs in young adults and is thought to reflect neoplastic transformation of thymic medullary B-cells. We characterized 59 PMBL cases from the Atlas of Blood Cancer Genomes Project. The cohort was predominantly young (median age 35), female (62%), and included individuals from diverse racial backgrounds. Most individuals presented with low-stage disease, favorable ECOG performance status, and high overall survival rate at last follow-up (89%). Whole transcriptome sequencing of 49 PMBL cases revealed gene expression profiles distinct from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), both activated B cell-like (ABC) and germinal center B cell-like (GCB) cell-of-origin subtypes. PMBLs showed significantly higher expression of thymic B cell-associated genes (p=0.032), supporting their presumed thymic origin. Whole exome and targeted sequencing confirmed recurrent mutations in JAK/STAT, NF-κB signaling, and DNA damage response pathways, with frequent aberrant somatic hypermutation (aSHM) affecting multiple genes. Recurrent copy number alterations included gains at 9p and 12, and losses at 13q. As in prior studies, CIITA rearrangements with diverse partners were recurrent. Although PMBL generally demonstrates excellent outcomes, aSHM-positive cases exhibited inferior progression-free survival (p=0.031), suggesting aSHM as a potential adverse prognostic marker. Our findings further refine the genomic landscape of PMBL and provide new insights into the biology of this neoplasm, with implications for prognostic stratification.

Cancer Research Communications
Cleveland Clinic (US), Mayo Clinic (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Duke University (US), University of Toronto (CA), Singapore General Hospital (SG), University of Illinois Chicago (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), Cleveland Clinic Florida (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US), NeoGenomics (United States) (US), Weill Cornell Medicine (US), Saint Louis University (US), Hamad Medical Corporation (QA), University of Rochester (US), Columbia University (US), Vanderbilt University Medical Center (US)
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon